Business Description
Herantis Pharma PLC
ISIN : FI4000087861
Compare
Compare
Traded in other countries / regions
HRTIS.FinlandHRPMF.USA IPO Date
2018-10-04Description
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson's disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 185.37 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.12 | |||||
| Interest Coverage | 7.33 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year FCF Growth Rate | 37.4 | |||||
| 3-Year Book Growth Rate | -31.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.39 | |||||
| Quick Ratio | 3.39 | |||||
| Cash Ratio | 3.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.3 | |||||
| Shareholder Yield % | -3.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | 29.88 | |||||
| ROA % | 4.64 | |||||
| ROIC % | 10.63 | |||||
| ROCE % | 7.85 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.98 | |||||
| Price-to-Tangible-Book | 6.05 | |||||
| EV-to-EBIT | 72.33 | |||||
| EV-to-EBITDA | 72.33 | |||||
| EV-to-FCF | -4.7 | |||||
| Price-to-Net-Current-Asset-Value | 6.05 | |||||
| Price-to-Net-Cash | 6.38 | |||||
| Earnings Yield (Greenblatt) % | 1.38 | |||||
| FCF Yield % | -16.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HRPMF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Herantis Pharma PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.119 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 3.51 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 3.51 - 3.51 | ||
| Shares Outstanding (Mil) | 16.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Herantis Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Herantis Pharma PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Herantis Pharma PLC Frequently Asked Questions
What is Herantis Pharma PLC(HRPMF)'s stock price today?
The current price of HRPMF is $3.51. The 52 week high of HRPMF is $3.51 and 52 week low is $3.51.
When is next earnings date of Herantis Pharma PLC(HRPMF)?
The next earnings date of Herantis Pharma PLC(HRPMF) is 2024-08-22.
Does Herantis Pharma PLC(HRPMF) pay dividends? If so, how much?
Herantis Pharma PLC(HRPMF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers